馬偕醫學大學機構典藏(MacKay Medical University Institutional Repository):Item 987654321/2820
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 1657/1756
Visitors : 3729163      Online Users : 180
RC Version 5.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search
LoginUploadHelpAboutAdminister
MMUIR > College of Medicine > Department of Optometry > Journal >  Item 987654321/2820

Please use this identifier to cite or link to this item: http://140.112.115.32:8080/ir/handle/987654321/2820

Title: VAS2870 and VAS3947 attenuate platelet activation and thrombus formation via a NOX-independent pathway downstream of PKC
Authors: Lu, Wan Jung;Li, Jiun Yi;Chen, Ray Jade;Huang, Li Ting;Lee, Tzu Yin;Lin, Kuan Hung
Contributors: 視光學系
Date: 2019-12-01
Issue Date: 2025-08-11 14:44:28 (UTC+8)
Abstract: NADPH oxidase (NOX) enzymes are involved in a various physiological and pathological processes such as platelet activation and inflammation. Interestingly, we found that the pan-NOX inhibitors VAS compounds (VAS2870 and its analog VAS3947) exerted a highly potent antiplatelet effect. Unlike VAS compounds, concurrent inhibition of NOX1, 2, and 4 by treatment with ML171, GSK2795039, and GKT136901/GKT137831 did not affect thrombin and U46619-induced platelet aggregation. These findings suggest that VAS compounds may inhibit platelet aggregation via a NOX-independent manner. Thus, we aimed to investigate the detailed antiplatelet mechanisms of VAS compounds. The data revealed that VAS compounds blocked various agonist-induced platelet aggregation, possibly via blocking PKC downstream signaling, including IKKβ and p38 MAPK, eventually reducing platelet granule release, calcium mobilization, and GPIIbIIIa activation. In addition, VAS compounds inhibited mouse platelet aggregation-induced by collagen and thrombin. The in vivo study also showed that VAS compounds delayed thrombus formation without affecting normal hemostasis. This study is the first to demonstrate that, in addition to inhibiting NOX activity, VAS compounds reduced platelet activation and thrombus formation through a NOX-independent pathway downstream of PKC. These findings also indicate that VAS compounds may be safe and potentially therapeutic agents for treating patients with cardiovascular diseases.
Relation: Scientific Reports, 9, 18852. https://doi.org/10.1038/s41598-019-55189-5
Appears in Collections:[Department of Optometry] Journal

Files in This Item:

File SizeFormat
index.html0KbHTML1View/Open


All items in MMUIR are protected by copyright, with all rights reserved.

 


DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback